Background Cahan's criteria have been utilized since 1948 to establish causality between prior radiation treatment and the development of secondary malignancy. One major criterion specifies that histological and radiographic evidence collected before and after radiation treatment must confirm separate tumor types; however, pretreatment biopsy is rarely obtained prior to radiosurgery for vestibular schwannoma and many other skull base and cranial lesions. Therefore, in these cases Cahan's criteria cannot be validly applied. Objective This article proposes an update to Cahan's criteria using modern molecular genetic analysis for cases lacking baseline histopathology. Methods Mate-pair sequencing and whole exome sequencing of a cerebellopontine angle undifferentiated high-grade pleomorphic sarcoma (UHGPS) that developed after stereotactic radiosurgery of a presumed benign vestibular schwannoma. Results Mate-pair sequencing and whole exome sequencing of the sarcoma revealed complex chromosomal aberrations. Notably, the tumor contained a deletion in the NF2 gene at 22q12 and an in-frame deletion on exon 5 of the remaining copy of NF2. Biallelic events impacting NF2 are atypical for UHGPS but are characteristic for vestibular schwannoma. These findings help support the conclusion that the UHGPS arose from a benign vestibular schwannoma all along. Conclusions Next-generation sequencing can be successfully applied to a radiationinduced sarcoma when both the original and malignant tumors harbor separate signature genetic markers. As our understanding of the genetic profile of various tumors expand, we believe that next-generation sequencing and other genomic tools will play an increasingly important role in establishing causality between radiation and the development of secondary malignancy.
Introduction
Radiation therapy has been an effective treatment of many benign and malignant lesions since inception in the late 19th century. [1] [2] [3] [4] However, it was not long before the risk of radiation-induced tumorigenesis was first recognized. Radiation-induced malignancies were initially described by Freiben et al in 1908 5 and subsequently, in 1948, Cahan et al 6 outlined the first diagnostic criteria for radiation-induced sarcoma (RIS). These criteria were rapidly adopted and modified to not only apply to sarcomas arising in irradiated bone, as was originally described, but to all malignancies that develop within the field of prior ionizing radiation. Murray et al 7 modified and expanded upon these criteria to clarify the latency period between radiation and malignancy. These modified criteria are the version universally applied today and include (1) the tumor must develop within the margins of the previously irradiated tissue; (2) histological and radiographic evidence collected before and after radiation treatment must confirm separate tumor types; (3) a significant latency period must exist between irradiation and RIS, typically longer than 5 years; and (4) the patient cannot have a predisposing condition to tumorigenesis. While these criteria have been effectively used to determine RIS for many years, current advancements in neurodiagnostic imaging and radiation delivery techniques used to treat many benign and malignant intracranial lesions have made criterion 2 difficult to achieve or adhere to. Specifically, many intracranial and skull base lesions can be accurately diagnosed and characterized on contrast enhanced magnetic resonance imaging (MRI) and/or thinly sliced computed tomography, and very rarely undergo histopathological confirmation via biopsy before treatment with Gamma-Knife (Elekta AB, Stockholm, Sweden), LINAC (e.g., Novalis [Brainlab, Munich, Germany] or CyberKnife [Accuray, Sunnyvale, California, United States]), or proton beam therapy. As these treatments are being more widely adopted, fewer patients are electing to undergo surgical resection as a baseline treatment. The true risk of radiation-induced malignancy after low-dose highly conformal radiation delivery remains unknown and highly contentious. Assessment of this risk is mired by the fact that most cases cannot completely fulfill Cahan's criteria without preradiation histological review. For example, in the case of a diagnosed malignancy after radiosurgery for a presumed benign vestibular schwannoma (VS), it remains unknown whether the original tumor was malignant all along, or if malignancy developed after treatment as a result of radiation effect or merely by pure coincidence.
Next-generation sequencing (NGS) has allowed us to efficiently and economically sequence whole exomes and genomes of human tissue with incredible accuracy. This technology has already been applied to genetic screening to evaluate for molecular predispositions to cancer and other diseases. Further, it has allowed us to examine the genetic profile of many benign and malignant neoplasms. For example, the National Cancer Institute and National Human Genome Research Institute have partnered to create The Cancer Genome Atlas, which has already generated comprehensive genetic profiles for 33 cancer types. With data generated from this initiative and other related work, we have the ability to rapidly and objectively determine the precise identity and lineage of a tumor. Based on this, we propose that NGS can be applied to investigate the association between radiation treatment and subsequent diagnosis of malignancy in cases where pretreatment histopathology is unavailable. Herein, we present a case example where this methodology is applied and discuss the utility of the strategy in the context of prior published cases. 
Methods

Mate-Pair DNA Library Preparation and Sequencing
Genomic deoxyribonucleic acid (DNA) from matched fresh frozen tumor and peripheral blood samples was isolated using the Qiagen Puregene extraction protocol (Qiagen, Hilden, Germany). The DNA was processed using the Illumina Nextera Mate Pair library protocol (Illumina, San Diego, California, United States) and sequenced on the Illumina HiSeq 2000 (Illumina, San Diego, California, United States). The sequencing produced 101-basepair paired-end fragments.
BMD Structural Variant Pipeline
The analysis pipeline for mate-pair sequencing (MPSeq) data are termed the BMD structural variant pipeline (Mayo Clinic, Rochester, Minnesota, United States). It was developed to find and report breakpoint junction locations and copy number variants (CNVs) from MPSeq data. The pipeline performs a two-step process on the sequencing data: alignment and structural variant analysis. Alignment is performed using the BIMA alignment method (Mayo Clinic, Rochester, Minnesota, United States). 8 The mapped sequences are passed to the structural variant analysis tools module, which consists of a junction detection step and a CNV detection step (unpublished data, November 2017). The junction detection step returns breakpoint junctions resulting from large structural variants (e.g., deletions, tandem duplications, inversions, and translocations). The CNV detection step segments the genome into regions and statistically determines whether there is a loss or gain in genetic material in that region. These losses and gains either result from structural variants, which should be supported by corresponding breakpoint junctions, or result from whole-arm or whole-chromosome aneuploidy, where breakpoint junctions are not present or difficult to report. ExomeSeq analysis of a control case of a confirmed benign VS sample revealed a single nucleotide frame-shift deletion variant in the NF2 gene (g.del29654678). This presumed pathogenic variant was one of only 24 variants that passed the high-confidence/high-impact filters. ExomeSeq analysis of the UHGPS in our previously reported index case revealed a nonrecurrent in-frame deletion variant in the NF2 gene at position g.del29654668. This variant was one of only 35 that passed the high-confidence/high-impact filters. In both the confirmed VS control sample and the UHGPS sample, the MPSeq/ExomeSeq analysis demonstrates an NF2 variant coupled with a loss of heterozygosity (LOH) in chromosome 22. Of note, the pathogenic deletions identified in both the VS and UHGPS were not identified in peripheral blood supporting that both were de novo somatic events. In both cases, this would result in the presence of a single, mutated allele of the NF2 gene that was present in the tumor alone or in a limited number of somatic tissues. This is in line with current literature that demonstrates 22 to 62% of VS contain a LOH of chromosome 22.
17-26 Furthermore, it has been reported that 30 to 66% of VS contain a double hit knockout of the NF2 gene, either from mutations or a mix of mutation and LOH.
17-24
Conversely, previously reported cases of UHGPS have lacked such specific chromosomal aberrations or mutations in chromosome 22. In the investigation of the genetic profile of UHGPS, Lewin 
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Discussion SRS is commonly employed for a wide range of benign and malignant intracranial and skull base lesions, such as VS, meningioma, pituitary tumors, metastases, and glioblastoma multiforme. 35, 36 While the occurrence of radiation-induced malignancy following conventional broad field external beam radiation has been well studied, the frequency at which this event occurs following SRS remains largely unknown and a topic of contentious debate. In this population, estimates are mired by the very low incidence of the event and the challenges of ascertaining causality using Cahan's criteria in the absence of pretreatment histology, as described by Loeffler et al. 37 Each item outlined in Cahan's criteria helps to establish increasing probability that the tumor in question developed as a result of prior irradiation. Therefore, the addition of independent determinants of causality will serve to further increase the diagnostic potential and utility of the criteria. To address the limitation commonly encountered in cases of SRS-not having pretreatment histology available for review-we explored the application of NGS to analyze the genetic profile of the malignant tumor to determine whether it shared any common characteristic features with the alleged progenitor neoplasm. This strategy may be particularly advantageous in cases were the malignant tumor and the presumed originating tumor each have their own separate pathognomonic mutations (e.g., NF2 gene in VS). Evaluating the case of malignancy developing after SRS for a sporadic VS as an example, we can assign different levels of probability of separate tumor types based upon the results of molecular genetic testing, with a caveat being that the patient does not harbor a germline pathogenic variant in the NF2 gene detected in 100% of reads from a peripheral blood sample.
• High probability that the malignant tumor arose from a benign VS: when the newly diagnosed malignant tumor does not typically include a pathologic variant (mutation) Modification of Cahan's Criteria Rusheen et al. 15
in the NF2 gene based upon published data; however, the surgical specimen reveals a concomitant pathologic variant in the NF2 gene.
• Intermediate probability that the malignant tumor arose from a benign VS: when the newly diagnosed malignant tumor contains a pathologic variant that has shown some evidence to be linked to VS, but it is either not exclusive to this tumor type or is not overwhelmingly seen.
• Low probability that the malignant tumor arose from a benign VS (i.e., may have been a malignant tumor all along): when genetic analysis of the tumor specimen fails to identify any pathologic variant in the NF2 gene or other genes implicated in VS such as LZTR1.
• Indeterminate probability that the malignant tumor arose from a benign VS: when the newly diagnosed malignant tumor is also known to commonly harbor a mutation on chromosome 22 and the NF2 gene based upon published data.
In this study, we introduce genetic analysis as a new modification to Cahan's criteria by applying it to a previously reported case.
14 In the original publication by Schmitt et al, the patient's presentation of unilateral hearing loss, no other associated cranial neuropathies, and MRI imaging demonstrating typical features of benign VS provided reasonable evidence that the tumor was in fact a benign schwannoma prior to radiation. However, as Kondziolka rightfully points out in an associated letter to the editor, 38 "because the original pathology was not known, this does not fulfill the Cahan criterion of a change in histology… Indeed, this tumor may have been an unrecognized sarcoma at presentation"-a fair criticism that plagues most other similar reports associated with SRS for VS. With no available preirradiation histology to satisfy criterion two, we sought NGS to identify genomic aberrations supportive of molecular transformation from an antecedent benign schwannoma. As outlined in ►Table 1, NF2/merlin genetic mutations have been robustly linked to VS. 39 For example, NF2 is caused by germline or somatic mosaic pathogenic variants in the NF2 gene resulting in bilateral VS in almost all patients. 40 Further, our review of the literature found the most recent study indicating a 59% incidence of NF2 genetic alterations in genomic DNA from sporadic VS with 33% demonstrating a double hit. 22 We suspect that the rate of NF2 mutations in VS is greater than 59%, and in our own experience we have found the number to approach 100% (unpublished data). Furthermore, our review of the literature found no published cases of UHGPS containing NF2 gene mutations or other frequent chromosome 22 aberrations. Because MPSeq/ExomeSeq analysis of the index RIS demonstrated an NF2 variant coupled with LOH in chromosome 22, based on a reasonable degree of scientific probability, we can conclude that the tumor was in fact originally a VS rather than being a sarcoma all along. Had the genetic analysis failed to identify any such variants, the evidence would strongly support that the malignancy did not arise from a VS. This novel strategy of examining the molecular footprint of a newly diagnosed malignancy to help determine the original tumor histology may be applied to other tumor types. Ewing sarcomas, for example, are almost 100% correlated with an EWS-FLI1 or EWS-ERG fusion transcript. 41 This fusion transcript is found in no other tumor types and is highly correlative. Therefore, finding this fusion transcript in a RIS tumor sample would provide conclusive evidence of the original tumor identity.
Conclusion
The application of Cahan's criteria, and the determination of what can and cannot be fairly deemed a radiation-induced neoplasm, has been the subject of much debate. Cahan's criteria are comprised of somewhat imprecise criteria that have undergone several revisions corresponding to medical advances. Molecular genetic analysis may provide valuable information in cases where no preirradiation histopathology is available-an increasingly common scenario with the more widespread use of radiosurgery. In this report, we demonstrate that NGS and mate-pair analysis can be successfully applied to a RIS when both the original and malignant tumor harbor established separate signature genetic markers. As our understanding of the genetic profile of various tumors expand, we believe that NGS, mate-pair analysis, and other genomic tools will play an increasingly important role in establishing causality between radiation and the development of secondary malignancy.
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